Stable expression and coexpression of human cytochrome P450 oxidoreductase and cytochrome P450 1A2 in V79 Chinese hamster cells: Sensitivity to quinones and biotransformation of 7-alkoxyresorufins and triazines

Drug Metabolism and Disposition

Volumn 24, Issue 12, 1996, Pages 1314-1319

  Schmalix, Wolfgang A ^a   Lang, Dieter ^b   Schneider, Anneliese ^a   Bocker, Ronald ^b   Greim, Helmut ^c   Doehmer, Johannes ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMETRYN; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 REDUCTASE; DOXORUBICIN; DUROQUINONE; MENADIONE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; RESORUFIN DERIVATIVE; TERBUTRYN; TRIAZINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CHO CELL; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TRANSFORMATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC ENGINEERING; NONHUMAN; PRIORITY JOURNAL; TOXICOKINETICS;

ANIMALS; BIOTRANSFORMATION; CELL LINE; CELL SURVIVAL; CHO CELLS; CRICETINAE; CYTOCHROME P-450 CYP1A2; GENETIC VECTORS; HUMANS; IMMUNOBLOTTING; NADH, NADPH OXIDOREDUCTASES; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXAZINES; QUINONES; RNA, MESSENGER; TRANSFECTION; TRIAZINES;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS;

EID: 0030454188     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. J. Doehmer and H. Greim: Cytochromes P450 in genetically engineered cell cultures: the gene technology approach. In "Cytochrome P450" (J. B. Schenkman and H. Greim, eds.), pp. 415-425. Springer Verlag, New York, 1993.
2. A. Schneider, W. A. Schmalix, V. Siruguri, E. de Groene, J. Horbach, B. Kleingeist, D. Lang, R. Böcker, C. Belloc, P. Beaune, H. Greim, and J. Doehmer: Stable expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells. Arch. Biochem. Biophys., 332, 295-304 (1996).
3. H. Murakami, Y. Yabusaki, and H. Ohkawa: Expression of rat NADPH-cytochrome P-450 reductase in Saccharomyces cerevisiae. DNA Cell. Biol. 5, 1-10 (1986).
4. 1. Arch. Biochem. Biophys. 300, 164-168 (1993).
5. H.-P. Eugster, S. Bärtsch, F. E. Würgler, and C. Sengstag: Functional co-expression of human oxidoreductase and cytochrome P450 1A1 in Saccharomyces cerevisiae results in increased EROD activity. Biochem. Biophys. Res. Commun. 185, 641-647 (1992).
6. C. Sengstag, H.-P. Eugster, and F. E. Würgler: High promutagen activating capacity of yeast microsomes containing human cytochrome P-450 1A and human NADPH-cytochrome P-450 reductase. Carcinogenesis (Lond.) 15, 837-844 (1994).
7. 5. Gene 125, 49-55 (1993).
8. 5, epoxide hydrolase and P-450. Biochem. Soc. Trans. 21, 1028-1034 (1993).
9. S. Tamura, K. R. Korzekwa, S. Kimura, H. V. Gelboin, and F. J. Gonzalez: Baculovirus-mediated expression and functional characterization of human NADPH-P-450 oxidoreductase. Arch. Biochem. Biophys. 293, 219-223 (1992).
10. 5. Eur. J. Biochem. 207, 109-116 (1992).
11. Y. Yanagawa, M. Sawada, T. Deguchi, F. J. Gonzalez, and T. Kamataki: Stable expression of human CYP1A2 and N-acetyltransferases in Chinese hamster CHL cells: mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. Cancer Res. 54, 3422-3427 (1994).
12. H. Murakami, Y. Yabusaki, T. Sakaki, M. Shibata, and H. Ohkawa: A genetically engineered P450 monooxygenase: construction of the functional fused enzyme between rat cytochrome P450s and NADPH-cytochrome P450 reductase. DNA Cell Biol. 6, 189-197 (1987).
13. M. Shibata, T. Sakaki, Y. Yabusaki, H. Murakami, and H. Ohkawa: Genetically engineered P450 monooxygenases: construction of bovine P450c17/ yeast reductase fused enzymes. DNA Cell Biol. 9, 27-36 (1990).
14. C. W. Fisher, M. S. Shet, D. L. Caudle, C. A. Martin-Wixtrom, and R. W. Estabrook: High-level expression in Escherichia coli of enzymatically active fusion proteins containing the domains of mammalian cytochromes P450 and NADPH-P450 reductase flavoprotein. Proc. Natl. Acad. Sci. U.S.A. 89, 10817-10821 (1992).
15. M. S. Shet, C. W. Fisher, P. L. Holmans, and R. W. Estabrook: Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc. Natl. Acad. Sci. U.S.A. 90, 11748-11752 (1993).
16. M. S. Shet, C. W. Fisher, M. P. Arlotto, C. H. L. Shackleton, P. L. Holmans, C. A. Martin-Wixtrom, Y. Saeki, and R. W. Estabrook: Purification and enzymatic properties of a recombinant fusion protein expressed in Escherichia coli containing the domains of bovine P450 17A and rat NADPH-P450 reductase. Arch. Biochem. Biophys. 311, 402-417 (1994).
17. H. Glatt, I. Gemperlein, G. Turchi, H. Heinritz, J. Doehmer, and F. Oesch: Search for cell culture systems with diverse xenobiotic-metabolizing activities and their use in toxicological studies. Mol. Toxicol. 1, 313-334 (1987).
18. J. Doehmer, A. Schneider, M. Faßbender V. Soballa, W. A. Schmalix, and H. Greim: Genetically engineered mammalian cells and applications. Toxicol. Lett. 82/83, 823-827 (1995).
19. A. V. Klotz, J. J. Stegeman, and M. R. Juchau: An alternative 7-ethoxyresorufin-O-deethylase activity assay: a continuous visible spectrophotometric method for measurement of cytochrome P-450 monooxygenase activity. Anal. Biochem. 140, 138-145 (1984).
20. H. R. Glatt, A. Seidel, O. Ribeiro, C. Kirkby, P. Hirom, and F. Oesch: Metabolic activation to a promutagen of 3-hydroxy-fram-7,8-dihydrobenzo[a]pyrene, a secondary metabolite of benzo[a]pyrene. Carcinogenesis (Lond) 8, 1621-1627 (1987).
21. C. Woelfel, B. Heinrich-Hirsch, T. Schulz-Schalge, A. Seidel, H. Frank, U. Ramp, F. Wächter, F. J. Wiebel, F. Gonzalez, H. Greim, and J. Doehmer: Genetically engineered V79 Chinese hamster cells for stable expression of human cytochrome P450 IA2. Eur. J. Pharmacol. 228, 95-102 (1992).
22. J. Doehmer and F. Oesch: V79 Chinese hamster cells genetically engineered for stable expression of cytochromes P450. Methods Enzymol. 206, 117-123 (1991).
23. W. A. Schmalix, H. Maser, F. Kiefer, R. Reen, F. J. Wiebel, F. Gonzalez, A. Seidel, H.-R. Glatt, H. Greim, and J. Doehmer: Stable expression of human cytochrome P450 1A1 cDNA in V79 Chinese hamster cells and metabolic activation of benzo[a]pyrene. Eur. J. Pharmacol. 248, 251-262 (1993).
24. M. M. Bradford: A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976).
25. S. Kubota, Y. Yoshida, H. Kumaoka, and A. Furumichi: Studies on the microsomal electron-transport system of anaerobically grown yeast. J. Biochem. (Tokyo) 81, 197-205 (1977).
26. M. D. Burke, S. Thompson, C. R. Elcombe, J. Halpert, T. Haaparanta, and R. T. Mayer: Ethoxy-, pentoxy-, and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34, 3337-3345 (1985).
27. D. Lang, D. Criegee, A. Grothusen, R. W. Saalfrank, and R. H. Böcker: In vitro metabolism of atrazine, terbutylazine, ametryne, and terbutryne in rats, pigs, and humans. Drug Metab. Dispos. 24, 859-865 (1996).
28. E. Borenfreund and J. A. Puerner: Toxicity determined in vitro by morphological alterations and neutral red uptake. Toxicol. Lett. 24, 119-124 (1985).
29. C. Labarca and K. Paigen: A simple, rapid and sensitive DNA assay procedure. Anal. Biochem. 102, 344-352 (1980).
30. G. Powis: Free radical formation by antitumor quinones. Free Radical Biol. Med. 6, 63-101 (1989).
31. G. Powis: Metabolism and reactions of quinoid anticancer agents. Pharmacol. Ther. 35, 57-162 (1987).
32. A. R. Goeptar, H. Scheerens, and N. P. E. Vermeulen: Oxygen and xenobiotic reductase activities of cytochrome P450. Crit. Rev. Toxicol. 25, 25-65 (1995).
33. D. R. Dutton, G. A. Reed, and A. Parkinson: Redox cycling of resorufin catalyzed by rat liver microsomal NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 268, 605-616 (1989).